HTDS - Hard to Treat Diseases (PINK)

[bdogsdad]

Nice.. No real change in PPS though. At this point, I'm not sure anyone believes all this is real. To much water under the bridge. They are going to have to release AUDITED financials in order to get the CE etc. removed.

[shockdragon]

SHENZHEN, China, March 1 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) and its China based subsidiary Mellow Hope announce that the company held Final Evaluation Meeting for Registration Approval of Cerebroprotein Hydrolysate for Injection medicine (Brand Name: Nutriprotein) in Mumbai, India.

HTDS held a successful Final Evaluation Meeting with the Indian DCGI (Drug Controller General of India) on its Cerebroprotein Hydrolysate for Injection. Mellow Hope has been conducting the clinical trials for the Indian market approval since April 2009. The company enters final stage of product quality testing, and will send new batch sample to the DCGI for quality reconfirmation by the end of March and, subsequently, DCGI will issue Registration Certificate for this medicine.

The company believes that, once approved, HTDS will be the only supplier of this product to India, and estimates Nutriprotein market size to 2 to 3 million doses annually.

Nutriprotein medicine is a unique brain nutrient that helps the Central Nervous System in regulating and improving nerve cell metabolism, promoting synapse generation, inducing nerve cell differentiation and protecting nerve cells against damages by ischemia, neurotoxins, etc.

The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link Mina Mar Marketing Group - Kayako SupportSuite Help Desk Software should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support site to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link The MinaMar Marketing Helpdesk.

To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at Mina Mar Group.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases

[shockdragon]

http://www.htdsmedical.com/docs/HTDS_FS_YE_2009.pdf

[shockdragon]

Hard to Treat Diseases (HTDS) Releases '09 Financials

Profits Over $600,000 USD

SHENZHEN, China, March 2 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) and its China based subsidiary Mellow Hope update shareholders on the company's 2009 revenues and profits.

With Fiscal Year ending on December 31st, HTDS announces that the company generated $5.39 million USD in Gross Revenues, with profits reaching $621,000 USD in 2009. The company gladly shares these sound numbers with the shareholders, and expects to increase its revenues in 2010. As the company does not subscribe to Pink Sheets filing service, the detailed financials are posted on HTDS IR company web site section "CLIENT SUPPORT" TAB, www.minamargroup.net, or this direct link Mina Mar Marketing Group - Kayako SupportSuite Help Desk Software, and HTDS web site.

A source close to HTDS, said, "We had a great 2009, and we don't expect any less from 2010. In 2009 we pushed our company deeper into the international vaccine trade, completed a number of solid deals and hoisted HTDS' name on the international markets. As 2010 progresses, we continue working on a number of promising market opportunities like those in India and Chile. HTDS internal projects are also well underway: We just completed the merger with Collagenna Skin Care which will market under the Melem Secrets brand. This will jumpstart our expansion into cosmetics market; and continue our assessment of the regenerative medicine and the stem cell bank projects in Europe. We have a lot on our plate today, but these substantial changes will create stronger and well-diversified HTDS for the future. Moving forward, revenues from Collagenna will also be included in our balance sheets."

The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB, www.minamargroup.net, or this direct link Mina Mar Marketing Group - Kayako SupportSuite Help Desk Software should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support site to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link The MinaMar Marketing Helpdesk.

Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas, where amongst other things they continuously spread false rumours, dark propaganda and innuendos in order to manipulate the trading patterns and thwart company plans for their own "quick profits" and self serving needs. The company and its supporters are monitoring these activities and those are promptly being reported on the Exposing Stock Bashers web site. Visit Exposing Stock Bashers and find out what criminal and civil actions the US authorities and others are taking against these individuals.

To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news releases, please subscribe or opt in mailer at Mina Mar Group.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases

Hard to Treat Diseases (HTDS) Releases '09 Financials

[stockman]

A must read

http://www.htdsmedical.com/docs/Coul...029%5B1%5D.pdf

[bdogsdad]

All good news but the share price is slow to react..

Way old, nothing ever happened, CE still there on pink's website.. Also, need for TD and Scott to allow buying of this security again. Otherwise what you see is about all you'll get.

[shockdragon]

OTTAWA, March 4 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) Further to the previously announced cosmetics merger (press release Feb 25, 2010) between Melem Secret's and Collagenna Skin Care Products, the company is providing an update as to how the 2 business models will operate.

Collagenna Skin Care Products Inc will take over the management of Melem's Secret and will look after all of the aspects of this company including product development.

Collagenna's CEO Michael Arnkvarn states: "Collagenna has not been very active in online direct sales as our main focus has been developing relationships with Professional Skin Care Clinics. We have developed some truly "retail" products that are designated to be used by the consumer. It is our intention to become very active in the huge US retail market and Melem's Secret will gradually become the main vehicle for online retail sales. The product mix between the two companies will be similar but not identical. Collagenna will continue to service and develop its existing client base. We will update our shareholders of our activities as they develop."

Melem Secret's website, Melem Secret, has been recently updated. A fully functional online store will be functional in the next several weeks. Collagenna, now part of HTDS, reminds its followers that products can be purchased online at Collagenna Skin Care Products web site as well at www.collagenna.com.

In other company news, the company has been receiving a number of calls from its followers regarding the Chile H1N1 orders and delivery by Mellow Hope to Chile. For example . BIOSANO Laboratorio ., (Image of HTDS CEO Terry Yuan 2nd from the left). Mr.Terry Yuan visiting HTDS agent in Chile, and the announcement that HTDS successfully supplied the H1N1 vaccine to Chile.

It appears to HTDS that as each shipment, or each additional put is fulfilled by Mellow Hope, the agents and or the cooperating and or coordinating representatives in Chile are updating their own web sites and issuing their own local news releases in Chile. HTDS has no control over this. The company does however confirm that the Chilean order is far greater than what was previously announced by HTDS dating back to November 2009. The reason for this, in abundance of caution HTDS management opted to release the minimum not the maximum Chilean order figures. The company did not feel that an additional news release of the increased orders was warranted. The company has since moved on to other business such as India projects and others soon to be released targets. In the circa of Q3 -Q4 of 2009, HTDS management did advise their followers that this Chilean order was quite a substantial one. HTDS provided the CEO' forward guidance opinion that HTDS is a grossly undervalued company both at the then and also the now current share prices. It appears that self regulators took issue with that forward guidance opinion, and placed a "Caveat Emptor" or the "skull and bones" icon rank on Pink Sheets. The HTDS management has already expressed its opinion that this is unfair, unwarranted and unjust.

With the newly merged Collagenna Skin Care into HTDS, increased revenues and profits, the HTDS management confirms its previous opinion that HTDS is and remains a grossly undervalued company. The latest mergers and events of HTDS should now become more amplified in the markets; as the company patiently and eagerly awaits a market correction. Moreover, as the Chile contract unveils itself over time, and additional puts of order are placed from Chile the additional revenues from this contract will be reflected in the future HTDS consolidated financial reports.

Additional information will be released as it becomes available.

Don't be a victim. Fight back! Report a stock basher! The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas, where amongst other things they continuously spread false rumors, dark propaganda and innuendos in order to manipulate the trading patterns and thwart company plans for their own "quick profits" and self serving needs. The company and its supporters are monitoring these activities and those are promptly being reported on the Exposing Stock Bashers web site. Visit Exposing Stock Bashers and find out what criminal and civil actions the US authorities are taking against web sites like Investorshub.com and other posters, and other medias which provide safe refuge to these individuals and the remedies available to you as an individual investor.

The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link Mina Mar Marketing Group - Kayako SupportSuite Help Desk Software should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link The MinaMar Marketing Helpdesk.

To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at Mina Mar Group.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases

Hard to Treat Diseases (HTDS) Collagenna Skin Care Business Model and Chilean Update

[bdogsdad]

0.0034 on that news.. Better than a sharp stick in the eye. Still no TD or Scott trade though. This will be a long climb back to the pennies.

[amulleady]

Never heard of this stock , and I am just starting to research, so thanks for the good stories to read...........

Looking at the charts.......have a potential back to the .015 range tops.....realistic??

[bdogsdad]

That's what we are hoping for..